Metabolic syndrome and atherosclerotic events in renal transplant recipients

Transplantation

Volumn 83, Issue 12, 2007, Pages 1577-1581

  Courivaud, Cécile ^a   Kazory, Amir ^a   Simula Faivre, Dominique ^a   Chalopin, Jean Marc ^a   Ducloux, Didier ^a,b  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b HÔPITAL SAINT JACQUES   (France)

Author keywords

Atherosclerosis; Kidney transplantation; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HAZARD RATIO; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

EID: 34250830213     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000266898.93894.3d     Document Type: Article

References (23)

1. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): Final report. Circulation 2002; 106: 3143.
2. de Vries APJ, Bakker SJL, van Son WJ, van der Heide JJH, Ploeg RJ, The HT, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4: 1675.
3. Porrini E, Delgado P, Bigo C, Alvarez A, Cobo M, Checa MD, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006; 48: 134.
4. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709.
5. Davidson J, Wilknson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceeding of an international expert panel meeting. Barcelona, Spain, 19 Feb. 2003. Transplantation 2003; 75(10 Suppl): SS3.
6. Hjelmesaeth J, Hartmann A, Midtvedt K, Aakhus S, Stenstrom J, Morkrid L, et al. Metabolic cardiovascular syndrome after renal transplantation. Transplantation 2001; 16: 1047.
7. Chunk JM, Lin CY, Curtis JJ. Variables affecting weight gain in renal transplant recipients. Am J Kidney Dis 2001; 38: 349.
8. Ducloux D, Kazory A, Simula-Faivre D, Chalopin JM. One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant 2005; 5: 2922.
9. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595.
10. Hjelmesaeth J, Midtvedt K, Jenssen T, Hartmann A. Insulin resistance after renal transplantation: Impact of immunosuppressive and antihypertensive drugs. Diabetes Care 2001; 24: 2121.
11. Menegazzo LA, Ursich MJ, Fukui RT, Rocha DM, Silva ME, Ianhez LE, et al. Mechanism of the diabetogenic action of Cyclosporin A. Horm Metab Res 1998; 30: 663.
12. Uchizono Y, Iwase M, Nakamura U, Sasaki N, Goto D, Iida M. Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling. Endocrinology 2004; 145: 2264.
13. Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Hayry PJ, Lemstrom KB. Cytomegalovirus infection and cardiac vasculopathy. Transplant Infect Dis 1999; 1: 115.
14. Moller DE. Potential role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000; 11: 212.
15. Nabipour I, Vahdat K, Jafari SM, Pazoki R, Sanjdideh Z. The association of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus type 1: The Persian Gulf Healthy Heart Study. Cardiovasc Diabetol 2006; 5: 25.
16. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
17. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study. J Am Soc Nephrol 2000; 11: 134.
18. Kiberd B, Keough-Ryan T, Panek R. Cardiovascular disease reduction in the outpatient kidney transplant clinic. Am J Transplant 2003; 3: 1393.
19. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Assessment of LEscol in Renal Transplantation (ALERT) study investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024.
20. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: A prospective study. Kidney Int 2004; 66: 441.
21. Ducloux D, Kazory A, Chalopin JM. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: A prospective study. Transplantation 2005; 79: 38.
22. Fellstrom B, Jardine AG, Soveri I, Cole F, Gronhagen-Riska C, Neumayer HH, et al. Assessment of Lescol in Renal Transplantation trial. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: Experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005; 79: 1160.
23. Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knopp RH, et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes 2003; 52: 172.